No abstract

In this postmenopausal Ecuadorian population the prevalence of the metabolic syndrome was high and its determinant factors related to age, time since menopause onset and sedentary habits. Because of the implications for cardiovascular risk, counseling programs directed toward high-risk populations should be encouraged.

In this postmenopausal Ecuadorian population, the frequency of menopausal symptoms, as assessed with the MENQOL, was found to be relatively similar to other Latin and non-Latin American populations and associated to age, hormonal status and related metabolic conditions.

No abstract

Introduction Inflammation is important for lung oncogenesis. Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to improve colorectal cancer survival; however, few have examined the association in lung cancer patients. Methods The VITamins And Lifestyle (VITAL) cohort includes Washington State residents, age 50 to 76 years who completed a baseline questionnaire between 2000 and 2002. Participants responded on the frequency and duration of use of individual NSAIDs in the previous 10 years. Subjects of this study were 785 members of the cohort who were identified with incident lung cancer from baseline through 2007 through linkage to a population-based cancer registry. Participants were followed for lung cancer death through linkage to state death records through 2009. Adjusted proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between NSAIDs and lung cancer death. Results 522 (66%) participants died from lung cancer. Relative to non-use, high (≥4 days/week and ≥4 years) pre-diagnostic use of regular-strength or low-dose aspirin (HR 0.99, 95% CI: 0.74–1.33 and HR 0.89, 95% CI: 0.67–1.17, respectively) or total non-aspirin NSAIDs (HR 1.20, 95% CI: 0.79–1.83) did not reduce lung cancer death. However, high use of ibuprofen was associated with a 62% increased risk of lung cancer death (HR 1.62, 95% CI: 1.01–2.58). Conclusions Long-term, pre-diagnostic NSAID use does not improve lung cancer survival overall. Use of ibuprofen may reduce survival from lung cancer. Our results underscore the need for further study of the mechanisms of action for individual NSAIDs with regard to cancer survival.